Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Production & Manufacturing
Process & Production
Return to: PBR Home | Production & Manufacturing | Process & Production

Process & Production

AIS HMI terminals optimize CIP in pharmaceutical plants By PBR Staff Writer
American Industrial Systems (AIS) is promoting Hygiene and Cleanliness-compliant operator interface terminal solutions for cleaning-in-place (CIP) in pharmaceutical, food and beverage processing plants.
Production & Manufacturing > Process & Production > News
Novozymes Biopharma initiates production of hyaluronic acid By PBR Staff Writer
Novozymes Biopharma, a part of Novozymes, has commenced the production and supply of hyaluronic acid at a new facility in China.
Production & Manufacturing > Process & Production > News ISCO develops new stem cell production methods By PBR Staff Writer
International Stem Cell Corporation (ISCO) has developed new technologies to produce human parthenogenetic stem cells (hpSC) designed for treating human diseases.
Production & Manufacturing > Process & Production > News
See more Process & Production news

Latest Process & Production News and Insight

View all Process & Production news or find news targeted to your interests
Angel Biotech acquires collagen plant in UK
14 May 2012 | By PBR Staff Writer
Angel Biotechmology Holdings (ABH) has acquired the biomaterial and collagen manufacturing business in Glasgow, UK, for a total cash consideration of £200,000.
Production & Manufacturing > Process & Production > News
Hydrogenation & Catalysis Tools
11 May 2012 | By HEL Group
HEL Group’s top quality high pressure reactors and systems offer innovative, robust and flexible solutions to chemists working on various hydrogenation and catalysis applications. The following is a quick selection guide; if your application is not described here, contact us to discuss your requirements - our systems are built to our customers’ requirements and specifications, and our design team is able to offer creative and innovative solutions to most challenges!
Production & Manufacturing > Process & Production > White Papers
Company & Overview
11 May 2012 | By HEL Group
HEL’s motto is better chemistry - faster; our products are designed to enable research chemists to achieve their goals faster, more accurately and more efficiently.
Production & Manufacturing > Process & Production > White Papers
HEL launches a new website to create a one-stop solution for thermal hazards and Calorimetry
11 May 2012
Thermal hazards and Calorimetry is a major field of expertise within HEL and this has grown to such an extent that we have launched a dedicated website. This is the first website of its kind in encompassing a wide range of thermal hazard and calorimetry products.
Production & Manufacturing > Process & Production > Press Releases
Ranbaxy plans new drug production facilities in Nigeria, Malaysia
10 May 2012 | By PBR Staff Writer
Ranbaxy Laboratories is planning to set up two new production facilities in Nigeria and Malaysia.
Production & Manufacturing > Process & Production > News
Multivac to present new packaging machine concept
09 May 2012 | By PBR Staff Writer
Multivac, a packaging company, will present a new machine concept for sensitive pharmaceutical and biotech products at Achema in Frankfurt.
Production & Manufacturing > Process & Production > News
UM gains funds from Pii for technology education and research
07 May 2012 | By PBR Staff Writer
Pharmaceutics International (Pii) has released funds to the University of Mississippi (UM) to support technology education and research.
Production & Manufacturing > Process & Production > News
Immuron joins Synlait to produce hyperimmune colostrum
07 May 2012
Australian biopharmaceutical company Immuron, a manufacturer of Travelan, has signed an agreement with New Zealand's Synlait Milk.
Production & Manufacturing > Process & Production > News
Almac installs UPS 4 blister line at US packaging facility
02 May 2012 | By PBR Staff Writer
Almac has installed Uhlmann blister line at its new 100,000ft2 US commercial packaging facility in Audubon, Pennsylvania.
Production & Manufacturing > Process & Production > News
View all Process & Production news or find news targeted to your interests

Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential 08 December 2010 GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500